AIC 521
Alternative Names: AIC-521Latest Information Update: 28 Sep 2023
At a glance
- Originator AiCuris
- Developer AiCuris; Merck & Co
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections; Gram-positive infections
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Gram-negative-infections in USA
- 28 Sep 2023 No recent reports of development identified for preclinical development in Gram-positive-infections in USA
- 23 Aug 2019 Preclinical trials in Gram-negative infections in USA (unspecified route) before August 2019 (Aicuris pipeline August 2019)